Inventor

Tak W. Mak

Inventor

Toronto, CA

Overview

31→

Patents

1982–2020

Patent span

Chemistry

Primary field (CPC C)

Patents· 31 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

C07Kprimary

C07KPeptides28%

A61KPreparations for medical, dental or toiletry purposes16%

C12NMicroorganisms or enzymes16%

A01KAnimal husbandry14%

A61PSpecific therapeutic activity of chemical compounds or medicinal preparations13%

G01NInvestigating or analysing materials by determining their chemical or physical properties7%

C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms3%

C10MLubricating compositions1%

C10NIndexing scheme associated with subclass c10m relating to lubricating compositions1%

C23FNon-mechanical removal of metallic material from surface1%

PatentTitleYear

10,822,388Methods and compositions for modulating toso activity2020 10,533,222Methods and compositions for detection of targets for autoimmune disease2020 10,024,844Identification of an inhibitor of iRhom1 or an inhibitor of iRhom22018 9,670,265'Methods and compositions for modulating toso activity'2017 9,624,289'Methods and compositions for modulating Toso activity'2017 9,493,561'Antibodies to Toso'2016 9,321,824'Methods and compositions for modulating Toso activity'2016 9,228,006'Methods and compositions for modulating Toso activity'2016 9,132,138'Method for the treatment of multiple sclerosis'2015 8,309,083'Polypeptides involved in immune response'2012 7,708,993'Polypeptides involved in immune response'2010 7,482,325'Downregulation of immune response by administering B7RP-2 fusion protein'2009 7,312,024'Materials and methods to inhibit Hodgkin and Reed Sternberg cell growth'2007 6,664,107'CD45 disrupted nucleic acid'2003 6,552,246'Transgenic mice comprising CD45 knockout'2003 6,468,528'Materials and methods to inhibit Hodgkin and Reed Sternberg cell growth'2002 5,907,079'MSH2 disrupted mice develop lymphomas'1999 5,786,152'Methods of inhibiting syp binding to a CTLA-4 receptor'1998 5,731,490'Mutant mouse lacking the expression of interferon regulatory factor 1 (IRF-1)'1998 5,714,667'Mice lacking expression of CTLA-4 receptor'1998 5,698,765'Mouse having a disrupted CD4 gene'1997 5,684,222'Mutant mouse having a disrupted TNFRp55'1997 5,675,059'Mouse lacking the expression of interferon regulatory factor 2 (IRF-2)'1997 5,625,122'Mouse having a disrupted lck gene'1997 5,616,491'Knockout mice'1997 5,557,032'Knockout mice'1996 5,532,158'Interleukin-2 receptor deficient mammals'1996 5,530,178'Mutant mouse lacking CD8 surface marker'1996 4,923,799'T cell specific cDNA clone'1990 4,713,332'T cell specific CDNA clone'1987 4,366,077'Temper rolling fluids'1982

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1982Based in Frankston, AU· patent location history

1987–1998Patents assigned to ONTARIO CANCER INST (11)· patent assignee history

1987–2020Based in Toronto, CA· patent location history

1998–2012Patents assigned to AMGEN CANADA INC (5)· patent assignee history

1998–2012Patents assigned to AMGEN INC (4)· patent assignee history

2003–2020Patents assigned to UNIV HEALTH NETWORK (9)· patent assignee history

2012Patents assigned to BLADT ANNA TAFURI (1)· patent assignee history

Inventor activity

Assignee and location history derived from the patent record.

Assignees

Assignee	Patents	Span
ONTARIO CANCER INST	11	1987–1998
UNIV HEALTH NETWORK	9	2003–2020
AMGEN CANADA INC	5	1998–2012
AMGEN INC	4	1998–2012
BLADT ANNA TAFURI	1	2012

Locations

Location	Patents	Span
Toronto, CA	30	1987–2020
Frankston, AU	1	1982